Overview

• NEJM-published ATTAIN-1 results show orforglipron cut body weight by an average 7.8%, 9.3% and 12.4% at 6, 12 and 36 mg over 72 weeks in 3,127 adults without diabetes, with improvements in multiple cardiometabolic measures.
• Adverse events with orforglipron were mainly mild to moderate gastrointestinal symptoms consistent with the GLP-1 class; the Eli Lilly–sponsored trial ran at 137 sites across nine countries.
• A Japanese multicenter observational study (n=92) found people who overeat in response to external food cues lost more weight on GLP-1 therapy than those who overeat for emotional reasons, suggesting behavioral screening could inform care.
• The eating-behavior findings are preliminary and based on self-reported measures, and the authors call for larger randomized trials and additional psychological support for patients with prominent emotional eating.
• Resalis Therapeutics’ RES-010, an antisense drug targeting miR-22, reduced fat mass with minimal lean-mass loss and limited weight regain in animals and has entered a Phase 1 trial in the Netherlands, with human efficacy and safety still unproven.